PureTech Health has amassed niche expertise and built a unique structure that allows it to develop technologies for unmet needs, in the separate but related areas of brain-immune-gut. And now, with the experienced ex-Sanofi CEO Chris Viehbacher as interim chair, PureTech can target a smooth path to its next growth stages in the “BIG Axis.” Senior executives Eric Elenko and Joep Muijrers reveal more about the focus and aims of the Boston, US group.

The Munich-based company is one of a handful of mature European biotechs poised to enter the big league. New CEO Jean-Paul Kress talks to In Vivo about the firm’s next generation antibody platform and why US expansion is crucial to its future.

In a recent Bain & Company survey, nearly 80% of health care executives said they needed to be more agile. Yet more than half said they were not familiar with formal agile methodologies and tools, and were not using them in their companies.

The rules behind product labeling have not undergone any significant revisions in the US and Europe for many years, but is this about to change?

In case you missed it: catch up with snippets from interviews published by In Vivo this month.

Castor, a cloud-based data solution, is enabling researchers to effectively capture and integrate data from any source. CEO and founder of the company, Derk Arts, spoke to In Vivo about the importance of cohesive data for the future use of artificial intelligence in biopharma.

Audiovisual media solutions provider Sony Corp. plays a largely unseen role in the success of end-user-facing capital equipment that manufacturers serve to the medtech sector. Product marketing manager for Sony Europe Healthcare Solutions, John Herman, explains Sony’s role in the industry, and how it is stepping up its focus on 4K imaging.

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Former Amgen R&D lead Sean Harper talks exclusively to In Vivo about his new role as a venture capitalist, joining veteran industry investor Beth Seidenberg as co-founder of Los Angeles-based Westlake Village BioPartners.

Europe’s patchwork of reimbursement agencies make it a daunting place for a small US biotech to do business. Traditionally large pharma partners or CMSOs have provided an experienced hand to hold, but as a new wave of gene therapies and orphan drugs get the EMA green light, smaller drug developers are applying innovation to commercialization and choosing to go solo.

A new digital ecosphere to support the efficient delivery of individualized cancer therapies to patients has been released by data and information management company EY. It is an open source framework that can be accessed by all stakeholders in the care delivery chain.

In case you missed it: catch up with snippets from interviews published by In Vivo this week.

During Q3, biopharma company fundraising reached $13.3bn, mostly from follow-on public offerings, which again made up the most of those dollars. Despite numerous deals valued at $100m+, M&A activity was the lowest of the year. Many of the biggest partnership deals were centered around the inflammation/immune area.

Sumitomo Dainippon Pharma paid $3bn up front in a wide-ranging deal involving multiple "vant" companies owned by Roivant. Lundbeck acquired what could be an important asset in the CGRP migraine market with the takeover of Alder for nearly $2bn in up-front and earn-out payments. Device financing surpassed pharma financing due to a $2bn debt offering by Alcon.

In the most recent installment of In Vivo's VC Playbook column, former Amgen R&D lead Sean Harper talks exclusively about his new role as a venture capitalist, joining veteran industry investor Beth Seidenberg as co-founder of Los Angeles-based Westlake Village BioPartners.